IND-10060558
type: ClinicalUseDefinition
node role: treeRoot
id:
  v: IND-10060558
meta:
  profile:
    v: http://fhir.ch/ig/ch-idmp/StructureDefinition/ch-idmp-clinicalusedefinition-indication
    l: ch-idmp-clinicalusedefinition-indication
text:
  status:
    v: generated
  div:
    v: Generated Narrative: ClinicalUseDefinition IND-10060558 Profile: ClinicalUseDefinition Indication type: Indication subject: MedicinalProductDefinition: extension = Film-coated tablet; identifier = http://fhir.ch/ig/ch-idmp/sid/mpid#Medical Product Identifier#CH-01100869-0672110010000; indication = Xospata wird angewendet für die Behandlung von erwachsenen Patienten, die an rezidivierter oder refraktärer akuter myeloider Leukämie (AML) mit FMS-ähnlichen Tyrosinkinase 3 (FLT3)-Mutationen leiden.; legalStatusOfSupply = A: Single dispensing requiring a medical or veterinary prescription; additionalMonitoringIndicator = No Warning; pediatricUseIndicator = Not authorised for the treatment in children; classification = gilteritinib,Synthetic indication DiseaseSymptomProcedures - Concept * Acute myeloid leukemia recurrent IntendedEffects - Concept * therapeutic
type:
  v: indication
subject:
  l: Xospata-Filmcoatedtablet
  reference:
    v: MedicinalProductDefinition/Xospata-Filmcoatedtablet

v: 10060558

v: Acute myeloid leukemia recurrent

v: 756005042000002

v: therapeutic